SCHEMBL6977074

SCHEMBL6977074

N#Cc1ccc(CCC(=O)N2CCCc3cc(N(CC(=O)Nc4ccccc4)Cc4ccccc4)ccc32)cc1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.45
FPR1 P21462 2/20 0.42
FPR2 P25090 2/20 0.42
NR3C1 P04150 1/20 0.42
RORC P51449 2/20 0.41
HSD17B10 Q99714 2/20 0.41
MAPT P10636 1/20 0.41
POLB P06746 1/20 0.39
TP53 P04637 1/20 0.39
ALDH1A1 P00352 2/20 0.39
MEN1 O00255 1/20 0.38
USP2 O75604 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6984164 0.91 KDM1A (0.43) KDM1ANR3C1HSD17B10MAPTTP53
SCHEMBL7090379 0.91 TP53 (0.45) KDM1ANR3C1HSD17B10MAPTTP53
SCHEMBL6979167 0.90 KDM1A (0.47) KDM1AFPR1FPR2NR3C1HSD17B10
Hydrochloric Acid SCHEMBL6980187 0.87 MAPT (0.39) NR3C1HSD17B10MAPTPOLBTP53
SCHEMBL6982684 0.87 KDM1A (0.43) KDM1ANR3C1HSD17B10MAPTTP53
SCHEMBL6980094 0.86 KDM1A (0.42) KDM1ANR3C1RORCHSD17B10MAPT
SCHEMBL6977076 0.84 RORC (0.41) KDM1AFPR1FPR2RORCHSD17B10
SCHEMBL6985998 0.83 NR3C1 (0.47) KDM1ANR3C1RORCHSD17B10MAPT
SCHEMBL6986003 0.83 RAB9A (0.48) FPR1FPR2NR3C1HSD17B10MAPT
SCHEMBL6986006 0.82 NR3C1 (0.46) KDM1ANR3C1RORCHSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0991624-B1 PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT BOEHRINGER INGELHEIM PHARMA (DE) 2003-11-19 EP disclosed
US-6300342-B1 FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION BOEHRINGER INGELHEIM PHARM KG (DE) 2001-10-09 US disclosed